Europe’s Medical Cannabis Market Expected to Reach USD 11 Billion by 2032

LOS ANGELES- The European medical cannabis market is projected to grow significantly, with its value reaching USD 11,093.7 million by 2032, up from USD 2,167.8 million in 2023. This reflects a compound annual growth rate (CAGR) of 19.3% between 2024 and 2032.

The expansion of this market is being driven by increasing legalization and the development of regulatory frameworks across European nations. Countries like Germany, Italy, the Netherlands, and the UK are leading this shift by creating comprehensive laws to manage cannabis production, distribution, and prescription for medical use. Germany, in particular, has become a key player since its legalization of medical cannabis in 2017, with strict regulations ensuring product quality and patient safety.

Research and development (R&D) investments are another critical factor in this market’s growth. There is a significant focus on exploring cannabis’ therapeutic potential, developing new treatment methods, and creating cannabis-based therapies for conditions such as chronic pain and epilepsy. This investment also extends to improving delivery systems, including oral formulations and transdermal patches, which aim to enhance patient outcomes.

The European Medicines Agency (EMA) continues to regulate the approval of cannabis-based treatments, ensuring that products meet stringent safety and quality standards.

In the UK, despite the absence of public healthcare reimbursement for cannabis treatments, the private market is experiencing growth. The number of private clinics offering medical cannabis has increased, with new treatment options becoming available at lower costs.

As R&D continues to advance and legalization expands, the European medical cannabis market is positioned for substantial growth over the next decade.

For more information, view the full report here: Request Sample.